{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T17:36:24Z","timestamp":1790616984195,"version":"4.1.0"},"reference-count":234,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.intimp.2022.109325","type":"journal-article","created":{"date-parts":[[2022,10,14]],"date-time":"2022-10-14T04:06:42Z","timestamp":1665720402000},"page":"109325","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":66,"special_numbering":"PA","title":["Role of CCL2\/CCR2 axis in the pathogenesis of COVID-19 and possible Treatments: All options on the Table"],"prefix":"10.1016","volume":"113","author":[{"given":"Mitra","family":"Ranjbar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Rahimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeinab","family":"Baghernejadan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atousa","family":"Ghorbani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hossein","family":"Khorramdelazad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2022.109325_b0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.micpath.2020.104554","article-title":"Immunopathological similarities between COVID-19 and influenza: investigating the consequences of Co-infection","volume":"152","author":"Khorramdelazad","year":"2021","journal-title":"Microb. Pathog."},{"key":"10.1016\/j.intimp.2022.109325_b0010","article-title":"Immunology, immunopathogenesis and immunotherapeutics of COVID-19; an overview","volume":"93","author":"Khosroshahi","year":"2021","journal-title":"Int. Immunopharmacol."},{"issue":"SI-1","key":"10.1016\/j.intimp.2022.109325_b0015","doi-asserted-by":"crossref","first-page":"571","DOI":"10.3906\/sag-2004-146","article-title":"COVID-19: prevention and control measures in community","volume":"50","author":"G\u00fcner","year":"2020","journal-title":"Turkish J. Medical Sci."},{"key":"10.1016\/j.intimp.2022.109325_b0020","unstructured":"WHO Coronavirus (COVID-19) Dashboard. [cited 2022 11.2.2022]; Available from: https:\/\/covid19.who.int\/."},{"issue":"4","key":"10.1016\/j.intimp.2022.109325_b0025","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/S2213-2600(20)30076-X","article-title":"Pathological findings of COVID-19 associated with acute respiratory distress syndrome","volume":"8","author":"Xu","year":"2020","journal-title":"Lancet Respir. Med."},{"issue":"7","key":"10.1016\/j.intimp.2022.109325_b0030","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1001\/jamainternmed.2020.0994","article-title":"Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China","volume":"180","author":"Wu","year":"2020","journal-title":"JAMA Internal Med."},{"issue":"5","key":"10.1016\/j.intimp.2022.109325_b0035","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/s41569-020-0360-5","article-title":"COVID-19 and the cardiovascular system","volume":"17","author":"Zheng","year":"2020","journal-title":"Nat. Rev. Cardiol."},{"issue":"1","key":"10.1016\/j.intimp.2022.109325_b0040","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/ane.13417","article-title":"The potential neurological effect of the COVID-19 vaccines: a review","volume":"144","author":"Lu","year":"2021","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.intimp.2022.109325_b0045","doi-asserted-by":"crossref","unstructured":"Z. Li et al., Caution on kidney dysfunctions of COVID-19 patients. 2020.","DOI":"10.1101\/2020.02.08.20021212"},{"issue":"6","key":"10.1016\/j.intimp.2022.109325_b0050","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1017\/dmp.2020.156","article-title":"Are Iranian sulfur mustard gas-exposed survivors more vulnerable to SARS-CoV-2? Some similarity in their pathogenesis","volume":"14","author":"Farnoosh","year":"2020","journal-title":"Disaster Medicine Public Health Preparedness"},{"key":"10.1016\/j.intimp.2022.109325_b0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2020.118097","article-title":"The bio-mission of interleukin-6 in the pathogenesis of COVID-19: A brief look at potential therapeutic tactics","volume":"257","author":"Abbasifard","year":"2020","journal-title":"Life Sci."},{"key":"10.1016\/j.intimp.2022.109325_b0060","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cyto.2016.05.025","article-title":"CXC chemokine CXCL12 tissue expression and circulating levels in peptic ulcer patients with Helicobacter pylori infection","volume":"85","author":"Bagheri","year":"2016","journal-title":"Cytokine"},{"key":"10.1016\/j.intimp.2022.109325_b0065","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.neuint.2016.12.013","article-title":"CCL2\/CCR2 signaling pathway in glioblastoma multiforme","volume":"103","author":"Vakilian","year":"2017","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.intimp.2022.109325_b0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2021.119034","article-title":"Role of CCL2\/CCR2 axis in the immunopathogenesis of rheumatoid arthritis: Latest evidence and therapeutic approaches","volume":"269","author":"Moadab","year":"2021","journal-title":"Life Sci."},{"issue":"4","key":"10.1016\/j.intimp.2022.109325_b0075","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s12079-018-00500-8","article-title":"Monocyte chemoattractant protein-1 (MCP-1\/CCL2) in diabetic retinopathy: latest evidence and clinical considerations","volume":"13","author":"Taghavi","year":"2019","journal-title":"J. Cell Commun. Signaling"},{"key":"10.1016\/j.intimp.2022.109325_b0080","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.cyto.2017.12.010","article-title":"A brief look at the role of monocyte chemoattractant protein-1 (CCL2) in the pathophysiology of psoriasis","volume":"110","author":"Behfar","year":"2018","journal-title":"Cytokine"},{"issue":"6","key":"10.1016\/j.intimp.2022.109325_b0085","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1038\/s41577-020-0331-4","article-title":"Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages","volume":"20","author":"Merad","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.intimp.2022.109325_b0090","doi-asserted-by":"crossref","unstructured":"Z. Zhou et al., Overly exuberant innate immune response to SARS-CoV-2 infection. 2020.","DOI":"10.2139\/ssrn.3551623"},{"issue":"4","key":"10.1016\/j.intimp.2022.109325_b0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.immuni.2021.03.005","article-title":"Longitudinal profiling of respiratory and systemic immune responses reveals myeloid cell-driven lung inflammation in severe COVID-19","volume":"54","author":"Szabo","year":"2021","journal-title":"Immunity"},{"key":"10.1016\/j.intimp.2022.109325_b0100","doi-asserted-by":"crossref","DOI":"10.1111\/imcb.12464","article-title":"Monocytes and macrophages in severe COVID-19\u2013friend, foe or both?","author":"Dress","year":"2021","journal-title":"Immunol. Cell Biol."},{"issue":"12","key":"10.1016\/j.intimp.2022.109325_b0105","doi-asserted-by":"crossref","first-page":"e13001","DOI":"10.15252\/emmm.202013001","article-title":"Altered bioenergetics and mitochondrial dysfunction of monocytes in patients with COVID-19 pneumonia","volume":"12","author":"Gibellini","year":"2020","journal-title":"EMBO Mol. Med."},{"issue":"6","key":"10.1016\/j.intimp.2022.109325_b0110","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/s41577-020-0311-8","article-title":"The trinity of COVID-19: immunity, inflammation and intervention","volume":"20","author":"Tay","year":"2020","journal-title":"Nat. Rev. Immunol."},{"issue":"6490","key":"10.1016\/j.intimp.2022.109325_b0115","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1126\/science.abb8925","article-title":"Cytokine release syndrome in severe COVID-19","volume":"368","author":"Moore","year":"2020","journal-title":"Science"},{"issue":"10223","key":"10.1016\/j.intimp.2022.109325_b0120","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"The lancet"},{"issue":"9","key":"10.1016\/j.intimp.2022.109325_b0125","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1016\/j.stemcr.2021.07.012","article-title":"Cardiomyocytes recruit monocytes upon SARS-CoV-2 infection by secreting CCL2","volume":"16","author":"Yang","year":"2021","journal-title":"Stem Cell Rep."},{"issue":"2","key":"10.1016\/j.intimp.2022.109325_b0130","first-page":"179","article-title":"Cytokine-targeted therapy in severely ill COVID-19 patients: options and cautions","volume":"4","author":"Rahmati","year":"2020","journal-title":"Ejmo"},{"issue":"1","key":"10.1016\/j.intimp.2022.109325_b0135","doi-asserted-by":"crossref","first-page":"20210006","DOI":"10.1098\/rsfs.2021.0006","article-title":"Potential therapeutic approaches for targeted inhibition of inflammatory cytokines following COVID-19 infection-induced cytokine storm","volume":"12","author":"Morgulchik","year":"2021","journal-title":"Interface focus"},{"key":"10.1016\/j.intimp.2022.109325_b0140","article-title":"Omicron variant and booster COVID-19 vaccines. The Lancet","author":"Burki","year":"2021","journal-title":"Respir. Med."},{"issue":"5","key":"10.1016\/j.intimp.2022.109325_b0145","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.immuni.2012.05.008","article-title":"The chemokine superfamily revisited","volume":"36","author":"Zlotnik","year":"2012","journal-title":"Immunity"},{"issue":"9","key":"10.1016\/j.intimp.2022.109325_b0150","doi-asserted-by":"crossref","first-page":"3652","DOI":"10.1073\/pnas.91.9.3652","article-title":"Monocyte chemoattractant protein 1 acts as a T-lymphocyte chemoattractant","volume":"91","author":"Carr","year":"1994","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"2","key":"10.1016\/j.intimp.2022.109325_b0155","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.canlet.2008.03.018","article-title":"The inflammatory chemokines CCL2 and CCL5 in breast cancer","volume":"267","author":"Soria","year":"2008","journal-title":"Cancer Lett."},{"issue":"21","key":"10.1016\/j.intimp.2022.109325_b0160","doi-asserted-by":"crossref","first-page":"6569","DOI":"10.1021\/bi9602270","article-title":"Heteronuclear (1H, 13C, 15N) NMR assignments and solution structure of the monocyte chemoattractant protein-1 (MCP-1) dimer","volume":"35","author":"Handel","year":"1996","journal-title":"Biochemistry"},{"issue":"1","key":"10.1016\/j.intimp.2022.109325_b0165","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/nsb0197-64","article-title":"The structure of MCP-1 in two crystal forms provides a rare example of variable quaternary interactions","volume":"4","author":"Lubkowski","year":"1997","journal-title":"Nat. Struct. Biol."},{"issue":"1","key":"10.1016\/j.intimp.2022.109325_b0170","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S1359-6101(99)00005-2","article-title":"The MCP\/eotaxin subfamily of CC chemokines","volume":"10","author":"Van Coillie","year":"1999","journal-title":"Cytokine Growth Factor Rev."},{"issue":"3","key":"10.1016\/j.intimp.2022.109325_b0175","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/0092-8674(83)90037-5","article-title":"Molecular cloning of gene sequences regulated by platelet-derived growth factor","volume":"33","author":"Cochran","year":"1983","journal-title":"Cell"},{"key":"10.1016\/j.intimp.2022.109325_b0180","doi-asserted-by":"crossref","DOI":"10.1002\/jcp.30375","article-title":"The molecular structure and role of CCL2 (MCP-1) and C-C chemokine receptor CCR2 in skeletal biology and diseases","author":"Zhu","year":"2021","journal-title":"J. Cell. Physiol."},{"issue":"6","key":"10.1016\/j.intimp.2022.109325_b0185","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1089\/jir.2008.0027","article-title":"Monocyte chemoattractant protein-1 (MCP-1): an overview","volume":"29","author":"Deshmane","year":"2009","journal-title":"J. Interferon Cytokine Res."},{"issue":"6","key":"10.1016\/j.intimp.2022.109325_b0190","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/nprot.2015.053","article-title":"The Phyre2 web portal for protein modeling, prediction and analysis","volume":"10","author":"Kelley","year":"2015","journal-title":"Nat. Protoc."},{"issue":"2","key":"10.1016\/j.intimp.2022.109325_b0195","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1042\/bj3130633","article-title":"Site-directed mutagenesis of monocyte chemoattractant protein-1 identifies two regions of the polypeptide essential for biological activity","volume":"313","author":"Beall","year":"1996","journal-title":"Biochem. J"},{"issue":"5","key":"10.1016\/j.intimp.2022.109325_b0200","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.4049\/jimmunol.153.5.2153","article-title":"Eosinophil transendothelial migration induced by cytokines. III. Effect of the chemokine RANTES","volume":"153","author":"Ebisawa","year":"1994","journal-title":"J. Immunol."},{"issue":"9","key":"10.1016\/j.intimp.2022.109325_b0205","doi-asserted-by":"crossref","first-page":"4851","DOI":"10.1128\/MCB.15.9.4851","article-title":"A dominant negative inhibitor indicates that monocyte chemoattractant protein 1 functions as a dimer","volume":"15","author":"Zhang","year":"1995","journal-title":"Mol. Cell. Biol."},{"issue":"3","key":"10.1016\/j.intimp.2022.109325_b0210","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1189\/jlb.1102577","article-title":"Expression and function of chemokines during viral infections: from molecular mechanisms to in vivo function","volume":"74","author":"Melchjorsen","year":"2003","journal-title":"J. Leukoc. Biol."},{"issue":"8","key":"10.1016\/j.intimp.2022.109325_b0215","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S0966-842X(03)00157-4","article-title":"Chemokines and viruses: friends or foes?","volume":"11","author":"Mahalingam","year":"2003","journal-title":"Trends Microbiol."},{"key":"10.1016\/j.intimp.2022.109325_b0220","doi-asserted-by":"crossref","DOI":"10.1016\/j.csbj.2021.01.034","article-title":"Chemokines and chemokine receptors during COVID-19 infection","author":"Khalil","year":"2021","journal-title":"Comput. Struct. Biotechnol. J."},{"issue":"Supplement_2","key":"10.1016\/j.intimp.2022.109325_b0225","doi-asserted-by":"crossref","first-page":"S152","DOI":"10.1086\/344266","article-title":"The chemokine system in neuroinflammation: an update","volume":"186","author":"Ransohoff","year":"2002","journal-title":"J. Infect. Dis."},{"issue":"1","key":"10.1016\/j.intimp.2022.109325_b0230","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1084\/jem.186.1.131","article-title":"An antagonist of monocyte chemoattractant protein 1 (MCP-1) inhibits arthritis in the MRL-lpr mouse model","volume":"186","author":"Gong","year":"1997","journal-title":"J. Exp. Med."},{"issue":"3","key":"10.1016\/j.intimp.2022.109325_b0235","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1046\/j.1365-2249.2002.01764.x","article-title":"Leucocyte chemotaxis: Examination of mitogen-activated protein kinase and phosphoinositide 3-kinase activation by Monocyte Chemoattractant Proteins-1,-2,-3 and-4","volume":"127","author":"Wain","year":"2002","journal-title":"Clin. Exp. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2022.109325_b0240","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1189\/jlb.1003479","article-title":"Synergy between proinflammatory ligands of G protein-coupled receptors in neutrophil activation and migration","volume":"76","author":"Gouwy","year":"2004","journal-title":"J. Leukoc. Biol."},{"issue":"7","key":"10.1016\/j.intimp.2022.109325_b0245","doi-asserted-by":"crossref","first-page":"3615","DOI":"10.4049\/jimmunol.152.7.3615","article-title":"Receptors and transduction pathways for monocyte chemotactic protein-2 and monocyte chemotactic protein-3. Similarities and differences with MCP-1","volume":"152","author":"Sozzani","year":"1994","journal-title":"J. Immunol."},{"issue":"9","key":"10.1016\/j.intimp.2022.109325_b0250","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1007\/s12272-013-0161-z","article-title":"Role of chemokine CCL2 and its receptor CCR2 in neurodegenerative diseases","volume":"36","author":"Bose","year":"2013","journal-title":"Arch. Pharmacal Res."},{"issue":"32","key":"10.1016\/j.intimp.2022.109325_b0255","doi-asserted-by":"crossref","first-page":"19084","DOI":"10.1074\/jbc.271.32.19084","article-title":"The amino-terminal extracellular domain of the MCP-1 receptor, but not the RANTES\/MIP-1\u03b1 receptor, confers chemokine selectivity: evidence for a two-step mechanism for MCP-1 receptor activation","volume":"271","author":"Monteclaro","year":"1996","journal-title":"J. Biol. Chem."},{"issue":"37","key":"10.1016\/j.intimp.2022.109325_b0260","doi-asserted-by":"crossref","first-page":"23186","DOI":"10.1074\/jbc.272.37.23186","article-title":"The amino-terminal domain of CCR2 is both necessary and sufficient for high affinity binding of monocyte chemoattractant protein 1: receptor activation by a pseudo-tethered ligand","volume":"272","author":"Monteclaro","year":"1997","journal-title":"J. Biol. Chem."},{"issue":"7","key":"10.1016\/j.intimp.2022.109325_b0265","doi-asserted-by":"crossref","first-page":"2752","DOI":"10.1073\/pnas.91.7.2752","article-title":"Molecular cloning and functional expression of two monocyte chemoattractant protein 1 receptors reveals alternative splicing of the carboxyl-terminal tails","volume":"91","author":"Charo","year":"1994","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"21","key":"10.1016\/j.intimp.2022.109325_b0270","doi-asserted-by":"crossref","first-page":"22294","DOI":"10.1074\/jbc.M311224200","article-title":"Identification of the glycosaminoglycan binding site of the CC chemokine, MCP-1: implications for structure and function in vivo","volume":"279","author":"Lau","year":"2004","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.intimp.2022.109325_b0275","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/j.1759-1961.2011.00024.x","article-title":"Role of CCR2 in immunobiology and neurobiology","volume":"3","author":"Yamasaki","year":"2012","journal-title":"Clin. Experimental Neuroimmunol."},{"key":"10.1016\/j.intimp.2022.109325_b0280","series-title":"Seminars in Immunology","article-title":"Regulation of NF-\u03baB by TNF family cytokines","author":"Hayden","year":"2014"},{"issue":"3","key":"10.1016\/j.intimp.2022.109325_b0285","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.3390\/ijms22031500","article-title":"Does CC Motif Chemokine Ligand 2 (CCL2) Link Obesity to a Pro-Inflammatory State?","volume":"22","author":"Dommel","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.intimp.2022.109325_b0290","first-page":"450","article-title":"Insulin inhibits NF\u03baB and MCP-1 expression in human aortic endothelial cells","volume":"86","author":"Aljada","year":"2001","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"9","key":"10.1016\/j.intimp.2022.109325_b0295","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1016\/j.celrep.2017.11.014","article-title":"Noncanonical pathway for regulation of CCL2 expression by an mTORC1-FOXK1 axis promotes recruitment of tumor-associated macrophages","volume":"21","author":"Nakatsumi","year":"2017","journal-title":"Cell Rep."},{"issue":"3","key":"10.1016\/j.intimp.2022.109325_b0300","first-page":"909","article-title":"Chemokines","volume":"90","author":"Rollins","year":"1997","journal-title":"Blood, J. Am. Soc. Hematol."},{"issue":"1","key":"10.1016\/j.intimp.2022.109325_b0305","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.coph.2011.10.015","article-title":"Chemokine mediated neuron\u2013glia communication and aberrant signalling in neuropathic pain states","volume":"12","author":"Old","year":"2012","journal-title":"Curr. Opin. Pharmacol."},{"issue":"1","key":"10.1016\/j.intimp.2022.109325_b0310","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1517\/14728222.7.1.35","article-title":"Targeting monocyte chemoattractant protein-1 signalling in disease","volume":"7","author":"Dawson","year":"2003","journal-title":"Expert opinion on therapeutic targets"},{"issue":"1\u20132","key":"10.1016\/j.intimp.2022.109325_b0315","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.jneuroim.2008.05.011","article-title":"The chemokine CCL2 activates p38 mitogen-activated protein kinase pathway in cultured rat hippocampal cells","volume":"199","author":"Cho","year":"2008","journal-title":"J. Neuroimmunol."},{"issue":"11","key":"10.1016\/j.intimp.2022.109325_b0320","doi-asserted-by":"crossref","first-page":"6010","DOI":"10.1074\/jbc.271.11.6010","article-title":"Inhibition of Monocyte Chemotaxis to CC Chemokines by Antisense Oligonucleotide for Cytosolic Phospholipase A2 (\u2217)","volume":"271","author":"Locati","year":"1996","journal-title":"J. Biol. Chem."},{"issue":"8","key":"10.1016\/j.intimp.2022.109325_b0325","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1038\/ni1222","article-title":"Pivotal function for cytoplasmic protein FROUNT in CCR2-mediated monocyte chemotaxis","volume":"6","author":"Terashima","year":"2005","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.intimp.2022.109325_b0330","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1172\/JCI5624","article-title":"MCP-1 deficiency reduces susceptibility to atherosclerosis in mice that overexpress human apolipoprotein B","volume":"103","author":"Gosling","year":"1999","journal-title":"J Clin Invest"},{"issue":"2","key":"10.1016\/j.intimp.2022.109325_b0335","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S1097-2765(00)80139-2","article-title":"Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor\u2013deficient mice","volume":"2","author":"Gu","year":"1998","journal-title":"Mol. Cell"},{"issue":"1","key":"10.1016\/j.intimp.2022.109325_b0340","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/S0165-5728(98)00002-2","article-title":"MCP-1, MCP-2 and MCP-3 expression in multiple sclerosis lesions: an immunohistochemical and in situ hybridization study","volume":"86","author":"McManus","year":"1998","journal-title":"J. Neuroimmunol."},{"issue":"6","key":"10.1016\/j.intimp.2022.109325_b0345","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1096\/fasebj.7.6.8472896","article-title":"Astrocyte expression of mRNA encoding cytokines IP-10 and JE\/MCP-1 in experimental autoimmune encephalomyelitis","volume":"7","author":"Ransohoff","year":"1993","journal-title":"FASEB J."},{"issue":"2","key":"10.1016\/j.intimp.2022.109325_b0350","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/S0165-5728(97)00208-7","article-title":"Expression of monocyte chemoattractant protein-1 and other \u03b2-chemokines by resident glia and inflammatory cells in multiple sclerosis lesions","volume":"84","author":"Simpson","year":"1998","journal-title":"J. Neuroimmunol."},{"issue":"1","key":"10.1016\/j.intimp.2022.109325_b0355","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/0165-5728(94)90220-8","article-title":"Regulation of monocyte chemoattractant protein-1 expression in adult human non-neoplastic astrocytes is sensitive to tumor necrosis factor (TNF) or antibody to the 55-kDa TNF receptor","volume":"50","author":"Barna","year":"1994","journal-title":"J. Neuroimmunol."},{"issue":"1","key":"10.1016\/j.intimp.2022.109325_b0360","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/ki.1992.266","article-title":"IL-1 receptor antagonist inhibits monocyte chemotactic peptide 1 generation by human mesangial cells","volume":"42","author":"Brown","year":"1992","journal-title":"Kidney Int."},{"issue":"13","key":"10.1016\/j.intimp.2022.109325_b0365","doi-asserted-by":"crossref","first-page":"5134","DOI":"10.1073\/pnas.87.13.5134","article-title":"Minimally modified low density lipoprotein induces monocyte chemotactic protein 1 in human endothelial cells and smooth muscle cells","volume":"87","author":"Cushing","year":"1990","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"15","key":"10.1016\/j.intimp.2022.109325_b0370","doi-asserted-by":"crossref","first-page":"9912","DOI":"10.1016\/S0021-9258(18)92905-4","article-title":"Alveolar macrophage-derived cytokines induce monocyte chemoattractant protein-1 expression from human pulmonary type II-like epithelial cells","volume":"266","author":"Standiford","year":"1991","journal-title":"J. Biol. Chem."},{"issue":"6","key":"10.1016\/j.intimp.2022.109325_b0375","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.4049\/jimmunol.142.6.1956","article-title":"Purification and amino acid analysis of two human monocyte chemoattractants produced by phytohemagglutinin-stimulated human blood mononuclear leukocytes","volume":"142","author":"Yoshimura","year":"1989","journal-title":"J. Immunol."},{"issue":"2","key":"10.1016\/j.intimp.2022.109325_b0380","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/0014-5793(89)80590-3","article-title":"Human monocyte chemoattractant protein-1 (MCP-1) Full-length cDNA cloning, expression in mitogen-stimulated blood mononuclear leukocytes, and sequence similarity to mouse competence gene JE","volume":"244","author":"Yoshimura","year":"1989","journal-title":"FEBS Lett."},{"issue":"1","key":"10.1016\/j.intimp.2022.109325_b0385","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1097\/MOH.0000000000000389","article-title":"The regulation and importance of monocyte chemoattractant protein-1","volume":"25","author":"Bianconi","year":"2018","journal-title":"Curr. Opin. Hematol."},{"issue":"5","key":"10.1016\/j.intimp.2022.109325_b0390","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1161\/01.RES.0000119170.70818.4F","article-title":"Essential role for Smad3 in regulating MCP-1 expression and vascular inflammation","volume":"94","author":"Feinberg","year":"2004","journal-title":"Circ. Res."},{"issue":"3","key":"10.1016\/j.intimp.2022.109325_b0395","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1002\/jlb.60.3.365","article-title":"Human recombinant monocyte chemotactic protein and other C-C chemokines bind and induce directional migration of dendritic cells in vitro","volume":"60","author":"Xu","year":"1996","journal-title":"J. Leukoc. Biol."},{"issue":"3\u20134","key":"10.1016\/j.intimp.2022.109325_b0400","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1080\/mic.10.3-4.247.257","article-title":"Monocyte chemoattractant protein-1 (CCL2) in inflammatory disease and adaptive immunity: therapeutic opportunities and controversies","volume":"10","author":"Daly","year":"2003","journal-title":"Microcirculation"},{"issue":"4","key":"10.1016\/j.intimp.2022.109325_b0405","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s004010100394","article-title":"CCR2A and CCR2B, the two isoforms of the monocyte chemoattractant protein-1 receptor are up-regulated and expressed by different cell subsets in idiopathic inflammatory myopathies","volume":"102","author":"Bartoli","year":"2001","journal-title":"Acta Neuropathol."},{"issue":"4","key":"10.1016\/j.intimp.2022.109325_b0410","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/emm.2007.55","article-title":"Expression of CCR2A, an isoform of MCP-1 receptor, is increased by MCP-1, CD40 ligand and TGF-\u03b2 in fibroblast like synoviocytes of patients with RA","volume":"39","author":"Cho","year":"2007","journal-title":"Exp. Mol. Med."},{"issue":"9","key":"10.1016\/j.intimp.2022.109325_b0415","doi-asserted-by":"crossref","first-page":"4877","DOI":"10.4049\/jimmunol.165.9.4877","article-title":"Functional differences between monocyte chemotactic protein-1 receptor A and monocyte chemotactic protein-1 receptor B expressed in a Jurkat T cell","volume":"165","author":"Sanders","year":"2000","journal-title":"J. Immunol."},{"issue":"6","key":"10.1016\/j.intimp.2022.109325_b0420","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.cyto.2005.06.016","article-title":"MCP-1-stimulated chemotaxis of monocytic and endothelial cells is dependent on activation of different signaling cascades","volume":"31","author":"Arefieva","year":"2005","journal-title":"Cytokine"},{"issue":"9","key":"10.1016\/j.intimp.2022.109325_b0425","doi-asserted-by":"crossref","first-page":"4129","DOI":"10.4049\/jimmunol.158.9.4129","article-title":"Differential CC chemokine-induced enhancement of T helper cell cytokine production","volume":"158","author":"Karpus","year":"1997","journal-title":"J. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2022.109325_b0430","first-page":"130","article-title":"Monocyte chemotactic protein expression during schistosome egg granuloma formation. Sequence of production, localization, contribution, and regulation","volume":"146","author":"Chensue","year":"1995","journal-title":"Am. J. Pathol."},{"issue":"6776","key":"10.1016\/j.intimp.2022.109325_b0435","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/35006097","article-title":"Control of TH2 polarization by the chemokine monocyte chemoattractant protein-1","volume":"404","author":"Gu","year":"2000","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.intimp.2022.109325_b0440","doi-asserted-by":"crossref","first-page":"4659","DOI":"10.4049\/jimmunol.168.9.4659","article-title":"Differential roles of CC chemokine ligand 2\/monocyte chemotactic protein-1 and CCR2 in the development of T1 immunity","volume":"168","author":"Traynor","year":"2002","journal-title":"J. Immunol."},{"issue":"9","key":"10.1016\/j.intimp.2022.109325_b0445","doi-asserted-by":"crossref","first-page":"4861","DOI":"10.4049\/jimmunol.169.9.4861","article-title":"Monocyte chemoattractant protein-1 selectively inhibits the acquisition of CD40 ligand-dependent IL-12-producing capacity of monocyte-derived dendritic cells and modulates Th1 immune response","volume":"169","author":"Omata","year":"2002","journal-title":"J. Immunol."},{"issue":"9","key":"10.1016\/j.intimp.2022.109325_b0450","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1084\/jem.194.9.1361","article-title":"Inflammatory chemokine transport and presentation in hev a remote control mechanism for monocyte recruitment to lymph nodes in inflamed tissues","volume":"194","author":"Palframan","year":"2001","journal-title":"J. Exp. Med."},{"issue":"11","key":"10.1016\/j.intimp.2022.109325_b0455","doi-asserted-by":"crossref","first-page":"4969","DOI":"10.4049\/jimmunol.153.11.4969","article-title":"CC chemokines induce the chemotaxis of NK and IL-2-activated NK cells. Role for G proteins","volume":"153","author":"Maghazachi","year":"1994","journal-title":"J. Immunol."},{"issue":"3","key":"10.1016\/j.intimp.2022.109325_b0460","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.4049\/jimmunol.179.3.1942","article-title":"IFN-\u03b3-mediated survival enables human neutrophils to produce MCP-1\/CCL2 in response to activation by TLR ligands","volume":"179","author":"Yoshimura","year":"2007","journal-title":"J. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2022.109325_b0465","article-title":"Functions of IL-4 and control of its expression","volume":"17","author":"Brown","year":"1997","journal-title":"Critical Rev.\u2122 Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2022.109325_b0470","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1084\/jem.188.1.157","article-title":"The coordinated action of CC chemokines in the lung orchestrates allergic inflammation and airway hyperresponsiveness","volume":"188","author":"Gonzalo","year":"1998","journal-title":"J. Exp. Med."},{"issue":"3","key":"10.1016\/j.intimp.2022.109325_b0475","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1128\/CVI.05532-11","article-title":"\u03b2-Galactomannan and Saccharomyces cerevisiae var. boulardii modulate the immune response against Salmonella enterica serovar Typhimurium in porcine intestinal epithelial and dendritic cells","volume":"19","author":"Badia","year":"2012","journal-title":"Clin. Vaccine Immunol."},{"issue":"6","key":"10.1016\/j.intimp.2022.109325_b0480","doi-asserted-by":"crossref","first-page":"e0129381","DOI":"10.1371\/journal.pone.0129381","article-title":"Disruption of the C. elegans intestinal brush border by the fungal lectin CCL2 phenocopies dietary lectin toxicity in mammals","volume":"10","author":"Stutz","year":"2015","journal-title":"PLoS ONE"},{"issue":"1","key":"10.1016\/j.intimp.2022.109325_b0485","doi-asserted-by":"crossref","first-page":"76","DOI":"10.2174\/138945011701151217110917","article-title":"The CCL2\/CCR2 axis in the pathogenesis of HIV-1 infection: a new cellular target for therapy?","volume":"17","author":"Angela Covino","year":"2016","journal-title":"Curr. Drug Targets"},{"issue":"1","key":"10.1016\/j.intimp.2022.109325_b0490","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/mi.2012.46","article-title":"IFN-\u03b1-driven CCL2 production recruits inflammatory monocytes to infection site in mice","volume":"6","author":"Conrady","year":"2013","journal-title":"Mucosal Immunol."},{"issue":"11","key":"10.1016\/j.intimp.2022.109325_b0495","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1038\/nri3070","article-title":"Monocyte recruitment during infection and inflammation","volume":"11","author":"Shi","year":"2011","journal-title":"Nat. Rev. Immunol."},{"issue":"12","key":"10.1016\/j.intimp.2022.109325_b0500","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1002\/eji.201141676","article-title":"CCL2: A potential prognostic marker and target of anti-inflammatory strategy in HIV\/AIDS pathogenesis","volume":"41","author":"Ansari","year":"2011","journal-title":"Eur. J. Immunol."},{"issue":"4","key":"10.1016\/j.intimp.2022.109325_b0505","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.coi.2005.05.009","article-title":"Pathogenesis of severe acute respiratory syndrome","volume":"17","author":"Lau","year":"2005","journal-title":"Curr. Opin. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2022.109325_b0510","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2334-4-34","article-title":"A human in vitro model system for investigating genome-wide host responses to SARS coronavirus infection","volume":"4","author":"Ng","year":"2004","journal-title":"BMC Infect. Dis."},{"issue":"3","key":"10.1016\/j.intimp.2022.109325_b0515","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1128\/JVI.01281-09","article-title":"Cellular immune responses to severe acute respiratory syndrome coronavirus (SARS-CoV) infection in senescent BALB\/c mice: CD4+ T cells are important in control of SARS-CoV infection","volume":"84","author":"Chen","year":"2010","journal-title":"J. Virol."},{"issue":"1","key":"10.1016\/j.intimp.2022.109325_b0520","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.virusres.2004.09.004","article-title":"SARS-coronavirus replication in human peripheral monocytes\/macrophages","volume":"107","author":"Yilla","year":"2005","journal-title":"Virus Res."},{"issue":"12","key":"10.1016\/j.intimp.2022.109325_b0525","doi-asserted-by":"crossref","first-page":"S88","DOI":"10.1038\/nm1143","article-title":"Severe acute respiratory syndrome","volume":"10","author":"Peiris","year":"2004","journal-title":"Nat. Med."},{"issue":"9","key":"10.1016\/j.intimp.2022.109325_b0530","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1093\/infdis\/jit504","article-title":"Active replication of Middle East respiratory syndrome coronavirus and aberrant induction of inflammatory cytokines and chemokines in human macrophages: implications for pathogenesis","volume":"209","author":"Zhou","year":"2014","journal-title":"J. Infect. Dis."},{"issue":"21","key":"10.1016\/j.intimp.2022.109325_b0535","doi-asserted-by":"crossref","first-page":"13800","DOI":"10.1128\/JVI.79.21.13800-13805.2005","article-title":"Severe acute respiratory syndrome coronavirus fails to activate cytokine-mediated innate immune responses in cultured human monocyte-derived dendritic cells","volume":"79","author":"Ziegler","year":"2005","journal-title":"J. Virol."},{"issue":"2","key":"10.1016\/j.intimp.2022.109325_b0540","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.chom.2016.01.007","article-title":"Dysregulated type I interferon and inflammatory monocyte-macrophage responses cause lethal pneumonia in SARS-CoV-infected mice","volume":"19","author":"Channappanavar","year":"2016","journal-title":"Cell Host Microbe"},{"issue":"9371","key":"10.1016\/j.intimp.2022.109325_b0545","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1016\/S0140-6736(03)13413-7","article-title":"Lung pathology of fatal severe acute respiratory syndrome","volume":"361","author":"Nicholls","year":"2003","journal-title":"The Lancet"},{"issue":"1","key":"10.1016\/j.intimp.2022.109325_b0550","doi-asserted-by":"crossref","first-page":"L25","DOI":"10.1152\/ajplung.2000.279.1.L25","article-title":"Phenotypic characterization of alveolar monocyte recruitment in acute respiratory distress syndrome","volume":"279","author":"Rosseau","year":"2000","journal-title":"Am. J. Physiol.-Lung Cellular Mol. Physiol."},{"issue":"20","key":"10.1016\/j.intimp.2022.109325_b0555","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1056\/NEJMoa030666","article-title":"A cluster of cases of severe acute respiratory syndrome in Hong Kong","volume":"348","author":"Tsang","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.intimp.2022.109325_b0560","doi-asserted-by":"crossref","unstructured":"H.R. Jonsdottir et al., Molnupiravir combined with different repurposed drugs further inhibits SARS-CoV-2 infection in human nasal epithelium in vitro. bioRxiv, 2022.","DOI":"10.1101\/2022.01.10.475377"},{"issue":"1","key":"10.1016\/j.intimp.2022.109325_b0565","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.clim.2008.03.460","article-title":"Chemokine-receptor upregulation and disease severity in respiratory syncytial virus infection","volume":"128","author":"Morrison","year":"2008","journal-title":"Clin. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2022.109325_b0570","doi-asserted-by":"crossref","first-page":"508","DOI":"10.4049\/jimmunol.1001002","article-title":"CCR2-antagonist prophylaxis reduces pulmonary immune pathology and markedly improves survival during influenza infection","volume":"186","author":"Lin","year":"2011","journal-title":"J. Immunol."},{"key":"10.1016\/j.intimp.2022.109325_b0575","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2020.118102","article-title":"Contribution of monocytes and macrophages to the local tissue inflammation and cytokine storm in COVID-19: Lessons from SARS and MERS, and potential therapeutic interventions","volume":"257","author":"Jafarzadeh","year":"2020","journal-title":"Life Sci."},{"key":"10.1016\/j.intimp.2022.109325_b0580","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.jcv.2017.03.003","article-title":"Serum IFN-\u03b3-induced protein 10 (IP-10) as a biomarker for severity of acute respiratory infection in healthy adults","volume":"90","author":"Hayney","year":"2017","journal-title":"J. Clin. Virol."},{"issue":"7","key":"10.1016\/j.intimp.2022.109325_b0585","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.91868","article-title":"M1-like monocytes are a major immunological determinant of severity in previously healthy adults with life-threatening influenza","volume":"2","author":"Cole","year":"2017","journal-title":"JCI insight"},{"issue":"8","key":"10.1016\/j.intimp.2022.109325_b0590","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1086\/428855","article-title":"Production of chemokines in the lungs of infants with severe respiratory syncytial virus bronchiolitis","volume":"191","author":"McNamara","year":"2005","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.intimp.2022.109325_b0595","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/j.csbj.2021.01.034","article-title":"Chemokines and chemokine receptors during COVID-19 infection","volume":"19","author":"Khalil","year":"2021","journal-title":"Comput. Struct. Biotechnol. J."},{"issue":"8","key":"10.1016\/j.intimp.2022.109325_b0600","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/S0046-8177(03)00367-8","article-title":"Lung pathology of severe acute respiratory syndrome (SARS): a study of 8 autopsy cases from Singapore","volume":"34","author":"Franks","year":"2003","journal-title":"Hum. Pathol."},{"issue":"6","key":"10.1016\/j.intimp.2022.109325_b0605","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.coviro.2011.10.026","article-title":"Type I interferons: diversity of sources, production pathways and effects on immune responses","volume":"1","author":"Swiecki","year":"2011","journal-title":"Curr. Opinion Virol."},{"key":"10.1016\/j.intimp.2022.109325_b0610","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.cytogfr.2020.05.003","article-title":"The cytokine storm in COVID-19: an overview of the involvement of the chemokine\/chemokine-receptor system","volume":"53","author":"Coperchini","year":"2020","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.intimp.2022.109325_b0615","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0065-2776(01)78002-9","article-title":"Chemokines in immunity","volume":"78","author":"Yoshie","year":"2001","journal-title":"Adv. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2022.109325_b0620","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41392-020-0211-1","article-title":"Temporal profiling of plasma cytokines, chemokines and growth factors from mild, severe and fatal COVID-19 patients","volume":"5","author":"Xu","year":"2020","journal-title":"Signal Transduction Targeted Ther."},{"issue":"3","key":"10.1016\/j.intimp.2022.109325_b0625","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1164\/ajrccm.154.3.8810593","article-title":"Inflammatory cytokines in patients with persistence of the acute respiratory distress syndrome","volume":"154","author":"Goodman","year":"1996","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"11","key":"10.1016\/j.intimp.2022.109325_b0630","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.3390\/ijms20112785","article-title":"Chemokines in COPD: from implication to therapeutic use","volume":"20","author":"Henrot","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.intimp.2022.109325_b0635","doi-asserted-by":"crossref","unstructured":"B.J. Rollins, A. Walz, M. Baggiolini, Recombinant human MCP-1\/JE induces chemotaxis, calcium flux, and the respiratory burst in human monocytes. 1991.","DOI":"10.1182\/blood.V78.4.1112.1112"},{"issue":"4","key":"10.1016\/j.intimp.2022.109325_b0640","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1073\/pnas.0334864100","article-title":"Glycosaminoglycan binding and oligomerization are essential for the in vivo activity of certain chemokines","volume":"100","author":"Proudfoot","year":"2003","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"11","key":"10.1016\/j.intimp.2022.109325_b0645","doi-asserted-by":"crossref","first-page":"6114","DOI":"10.4049\/jimmunol.0904177","article-title":"The role of the CCL2\/CCR2 axis in mouse mast cell migration in vitro and in vivo","volume":"184","author":"Collington","year":"2010","journal-title":"J. Immunol."},{"issue":"3\u20134","key":"10.1016\/j.intimp.2022.109325_b0650","first-page":"273","article-title":"Significant involvement of CCL2 (MCP-1) in inflammatory disorders of the lung","volume":"10","author":"Rose","year":"2003","journal-title":"Microcirculation"},{"issue":"6","key":"10.1016\/j.intimp.2022.109325_b0655","doi-asserted-by":"crossref","first-page":"3273","DOI":"10.4049\/jimmunol.170.6.3273","article-title":"Monocytes are potent facilitators of alveolar neutrophil emigration during lung inflammation: role of the CCL2-CCR2 axis","volume":"170","author":"Maus","year":"2003","journal-title":"J. Immunol."},{"issue":"4","key":"10.1016\/j.intimp.2022.109325_b0660","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.4049\/jimmunol.163.4.2193","article-title":"Differential monocyte chemoattractant protein-1 and chemokine receptor 2 expression by murine lung fibroblasts derived from Th1-and Th2-type pulmonary granuloma models","volume":"163","author":"Hogaboam","year":"1999","journal-title":"J. Immunol."},{"key":"10.1016\/j.intimp.2022.109325_b0665","doi-asserted-by":"crossref","unstructured":"M. Buszko et al., The dynamic changes in cytokine responses in COVID-19: a snapshot of the current state of knowledge. 2020, Nature Publishing Group.","DOI":"10.1038\/s41590-020-0779-1"},{"issue":"5","key":"10.1016\/j.intimp.2022.109325_b0670","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1093\/infdis\/jiaa363","article-title":"Serum cytokine and chemokine profile in relation to the severity of coronavirus disease 2019 in China","volume":"222","author":"Chi","year":"2020","journal-title":"J. Infect. Dis."},{"issue":"5","key":"10.1016\/j.intimp.2022.109325_b0675","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/j.cell.2020.04.026","article-title":"Imbalanced host response to SARS-CoV-2 drives development of COVID-19","volume":"181","author":"Blanco-Melo","year":"2020","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.intimp.2022.109325_b0680","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.jaci.2020.04.027","article-title":"Plasma IP-10 and MCP-3 levels are highly associated with disease severity and predict the progression of COVID-19","volume":"146","author":"Yang","year":"2020","journal-title":"J. Allergy Clin. Immunol."},{"issue":"6","key":"10.1016\/j.intimp.2022.109325_b0685","doi-asserted-by":"crossref","first-page":"e02749","DOI":"10.1128\/mBio.02749-21","article-title":"CCR2 Signaling Restricts SARS-CoV-2 Infection","volume":"12","author":"Vanderheiden","year":"2021","journal-title":"MBio"},{"key":"10.1016\/j.intimp.2022.109325_b0690","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.842949","article-title":"Myeloid-Derived Suppressor Cells in COVID-19: The Paradox of Good","volume":"13","author":"Grassi","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2022.109325_b0695","unstructured":"S. Falck-Jones et al., Functional myeloid-derived suppressor cells expand in blood but not airways of COVID-19 patients and predict disease severity. medRxiv, 2020."},{"issue":"7","key":"10.1016\/j.intimp.2022.109325_b0700","doi-asserted-by":"crossref","first-page":"947","DOI":"10.17219\/acem\/70065","article-title":"Myeloid-derived suppressor cell accumulation in renal cell carcinoma is correlated with CCL2, IL-17 and IL-18 expression in blood and tumors","volume":"27","author":"Guan","year":"2018","journal-title":"Adv. Clin. Experimental Medicine"},{"issue":"4","key":"10.1016\/j.intimp.2022.109325_b0705","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1002\/iid3.523","article-title":"CCL2 produced by pancreatic ductal adenocarcinoma is essential for the accumulation and activation of monocytic myeloid-derived suppressor cells","volume":"9","author":"Gu","year":"2021","journal-title":"Immun. Inflammation Dis."},{"key":"10.1016\/j.intimp.2022.109325_b0710","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2022.109024","article-title":"Myeloid-derived suppressor cells in COVID-19: a review","author":"Perfilyeva","year":"2022","journal-title":"Clin. Immunol."},{"issue":"11","key":"10.1016\/j.intimp.2022.109325_b0715","doi-asserted-by":"crossref","first-page":"5546","DOI":"10.3390\/app12115546","article-title":"Changing dynamics of SARS-CoV-2: a global challenge","volume":"12","author":"Chugh","year":"2022","journal-title":"Appl. Sci."},{"issue":"11","key":"10.1016\/j.intimp.2022.109325_b0720","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1001\/jama.2021.2294","article-title":"SARS-CoV-2 variants of concern in the United States\u2014challenges and opportunities","volume":"325","author":"Walensky","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.intimp.2022.109325_b0725","unstructured":"SARS-CoV-2 Variant Classifications and Definitions. 2022 [cited 2022 26.4.2022]; Available from: https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/variants\/variant-classifications.html?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fcoronavirus%2F2019-ncov%2Fvariants%2Fvariant-info.html."},{"key":"10.1016\/j.intimp.2022.109325_b0730","doi-asserted-by":"crossref","unstructured":"M. Ramanathan et al., SARS-CoV-2 B. 1.1. 7 and B. 1.351 spike variants bind human ACE2 with increased affinity. Lancet Infect. Dis. 21(8) (2021) 1070.","DOI":"10.1016\/S1473-3099(21)00262-0"},{"issue":"10","key":"10.1016\/j.intimp.2022.109325_b0735","doi-asserted-by":"crossref","first-page":"7045","DOI":"10.1002\/jcp.30367","article-title":"Higher infectivity of the SARS-CoV-2 new variants is associated with K417N\/T, E484K, and N501Y mutants: an insight from structural data","volume":"236","author":"Khan","year":"2021","journal-title":"J. Cell. Physiol."},{"issue":"2","key":"10.1016\/j.intimp.2022.109325_b0740","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.jpha.2020.03.001","article-title":"Molecular immune pathogenesis and diagnosis of COVID-19","volume":"10","author":"Li","year":"2020","journal-title":"J. Pharm. Anal."},{"issue":"1","key":"10.1016\/j.intimp.2022.109325_b0745","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3390\/biom11010091","article-title":"Cytokines and chemokines in SARS-CoV-2 infections\u2014therapeutic strategies targeting cytokine storm","volume":"11","author":"Pum","year":"2021","journal-title":"Biomolecules"},{"issue":"11","key":"10.1016\/j.intimp.2022.109325_b0750","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1038\/s41590-020-0778-2","article-title":"SARS-CoV-2 infection of human ACE2-transgenic mice causes severe lung inflammation and impaired function","volume":"21","author":"Winkler","year":"2020","journal-title":"Nat. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2022.109325_b0755","doi-asserted-by":"crossref","first-page":"e1009195","DOI":"10.1371\/journal.ppat.1009195","article-title":"K18-hACE2 mice develop respiratory disease resembling severe COVID-19","volume":"17","author":"Yinda","year":"2021","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.intimp.2022.109325_b0760","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.629193","article-title":"SARS-CoV-2 causes a different cytokine response compared to other cytokine storm-causing respiratory viruses in severely ill patients","volume":"12","author":"Olbei","year":"2021","journal-title":"Front. Immunol."},{"issue":"7","key":"10.1016\/j.intimp.2022.109325_b0765","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.110387","article-title":"SARS-CoV-2 variants of concern display enhanced intrinsic pathogenic properties and expanded organ tropism in mouse models","volume":"38","author":"Stolp","year":"2022","journal-title":"Cell Rep."},{"issue":"16","key":"10.1016\/j.intimp.2022.109325_b0770","doi-asserted-by":"crossref","first-page":"9058","DOI":"10.3390\/ijms23169058","article-title":"A Comparative Study of the Plasma Chemokine Profile in COVID-19 Patients Infected with Different SARS-CoV-2 Variants","volume":"23","author":"Korobova","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.intimp.2022.109325_b0775","doi-asserted-by":"crossref","first-page":"27","DOI":"10.3390\/v14010027","article-title":"SARS-CoV-2 variants of concern infect the respiratory tract and induce inflammatory response in wild-type laboratory mice","volume":"14","author":"Stone","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.intimp.2022.109325_b0780","first-page":"e02371","article-title":"Immunological and Pathological Peculiarity of Severe Acute Respiratory Syndrome Coronavirus 2 Beta Variant","author":"Lee","year":"2022","journal-title":"Microbiol. Spectrum"},{"key":"10.1016\/j.intimp.2022.109325_b0785","doi-asserted-by":"crossref","unstructured":"P. Radvak et al., B. 1.1. 7 and B. 1.351 variants are highly virulent in K18-ACE2 transgenic mice and show different pathogenic patterns from early SARS-CoV-2 strains. bioRxiv, 2021.","DOI":"10.1101\/2021.06.05.447221"},{"issue":"1","key":"10.1016\/j.intimp.2022.109325_b0790","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1080\/22221751.2021.1872351","article-title":"Characterization of SARS-CoV-2 ORF6 deletion variants detected in a nosocomial cluster during routine genomic surveillance, Lyon, France","volume":"10","author":"Qu\u00e9rom\u00e8s","year":"2021","journal-title":"Emerging Microbes Infections"},{"issue":"3","key":"10.1016\/j.intimp.2022.109325_b0795","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.clim.2007.08.001","article-title":"Monocyte chemoattractant protein 1 contributes to an adequate immune response in influenza pneumonia","volume":"125","author":"Dessing","year":"2007","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.intimp.2022.109325_b0800","first-page":"482","article-title":"Non-myeloid cells are major contributors to innate immune responses via production of monocyte chemoattractant protein-1\/CCL2","author":"Yoshimura","year":"2014","journal-title":"Front. Immunol."},{"issue":"4","key":"10.1016\/j.intimp.2022.109325_b0805","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1111\/febs.14277","article-title":"A drug development perspective on targeting tumor-associated myeloid cells","volume":"285","author":"Majety","year":"2018","journal-title":"FEBS J."},{"issue":"8","key":"10.1016\/j.intimp.2022.109325_b0810","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1002\/art.21975","article-title":"A randomized controlled trial with an anti-CCL2 (anti\u2013monocyte chemotactic protein 1) monoclonal antibody in patients with rheumatoid arthritis","volume":"54","author":"Haringman","year":"2006","journal-title":"Arthritis & Rheumatism: Official J. Am. College Rheumatol."},{"issue":"6","key":"10.1016\/j.intimp.2022.109325_b0815","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1183\/13993003.01558-2014","article-title":"CC-chemokine ligand 2 inhibition in idiopathic pulmonary fibrosis: a phase 2 trial of carlumab","volume":"46","author":"Raghu","year":"2015","journal-title":"Eur. Respir. J."},{"issue":"3","key":"10.1016\/j.intimp.2022.109325_b0820","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1007\/s10637-012-9869-8","article-title":"Phase 2 study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 (CCL2), in metastatic castration-resistant prostate cancer","volume":"31","author":"Pienta","year":"2013","journal-title":"Invest. New Drugs"},{"issue":"4","key":"10.1016\/j.intimp.2022.109325_b0825","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1007\/s00280-013-2099-8","article-title":"A first-in-human, first-in-class, phase I study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 in patients with solid tumors","volume":"71","author":"Sandhu","year":"2013","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"4","key":"10.1016\/j.intimp.2022.109325_b0830","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1007\/s10517-016-3201-0","article-title":"Ingramon, a peptide inhibitor of MCP-1 chemokine, reduces migration of blood monocytes stimulated by glioma-conditioned medium","volume":"160","author":"Krasnikova","year":"2016","journal-title":"Bull. Exp. Biol. Med."},{"issue":"10","key":"10.1016\/j.intimp.2022.109325_b0835","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1007\/s00011-011-0356-z","article-title":"Synthetic peptide fragment (65\u201376) of monocyte chemotactic protein-1 (MCP-1) inhibits MCP-1 binding to heparin and possesses anti-inflammatory activity in stable angina patients after coronary stenting","volume":"60","author":"Arefieva","year":"2011","journal-title":"Inflamm. Res."},{"issue":"5","key":"10.1016\/j.intimp.2022.109325_b0840","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1136\/annrheumdis-2016-210426","article-title":"CCL2\/CCR2, but not CCL5\/CCR5, mediates monocyte recruitment, inflammation and cartilage destruction in osteoarthritis","volume":"76","author":"Raghu","year":"2017","journal-title":"Ann. Rheum. Dis."},{"issue":"8","key":"10.1016\/j.intimp.2022.109325_b0845","first-page":"3282","article-title":"Significance of macrophage chemoattractant protein-1 in macrophage recruitment, angiogenesis, and survival in human breast cancer","volume":"6","author":"Ueno","year":"2000","journal-title":"Clin. Cancer Res."},{"issue":"6","key":"10.1016\/j.intimp.2022.109325_b0850","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1002\/ijc.24378","article-title":"Stromal MCP-1 in mammary tumors induces tumor-associated macrophage infiltration and contributes to tumor progression","volume":"125","author":"Fujimoto","year":"2009","journal-title":"Int. J. Cancer"},{"issue":"1","key":"10.1016\/j.intimp.2022.109325_b0855","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s00428-018-2461-7","article-title":"High expression of CCL2 in tumor cells and abundant infiltration with CD14 positive macrophages predict early relapse in breast cancer","volume":"474","author":"Heiskala","year":"2019","journal-title":"Virchows Arch."},{"issue":"5","key":"10.1016\/j.intimp.2022.109325_b0860","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1002\/1097-0142(20010901)92:5<1085::AID-CNCR1424>3.0.CO;2-K","article-title":"Significant correlation of monocyte chemoattractant protein-1 expression with neovascularization and progression of breast carcinoma","volume":"92","author":"Saji","year":"2001","journal-title":"Cancer: Interdisciplinary Int. J. Am. Cancer Soc."},{"issue":"3","key":"10.1016\/j.intimp.2022.109325_b0865","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1111\/cas.14306","article-title":"Phase I dose-escalation trial to repurpose propagermanium, an oral CCL2 inhibitor, in patients with breast cancer","volume":"111","author":"Masuda","year":"2020","journal-title":"Cancer Sci."},{"issue":"7525","key":"10.1016\/j.intimp.2022.109325_b0870","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/nature13862","article-title":"Cessation of CCL2 inhibition accelerates breast cancer metastasis by promoting angiogenesis","volume":"515","author":"Bonapace","year":"2014","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.intimp.2022.109325_b0875","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s10787-020-00773-9","article-title":"The role and therapeutic potential of NF-kappa-B pathway in severe COVID-19 patients","volume":"29","author":"Hariharan","year":"2021","journal-title":"Inflammopharmacology"},{"key":"10.1016\/j.intimp.2022.109325_b0880","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.molimm.2017.01.009","article-title":"Tumor necrosis factor-alpha inhibitors suppress CCL2 chemokine in monocytes via epigenetic modification","volume":"83","author":"Lin","year":"2017","journal-title":"Mol. Immunol."},{"issue":"6","key":"10.1016\/j.intimp.2022.109325_b0885","first-page":"2763","article-title":"Diallyl disulfide inhibits TNF\u03b1-induced CCL2 release by MDA-MB-231 cells","volume":"34","author":"Bauer","year":"2014","journal-title":"Anticancer Res."},{"issue":"1","key":"10.1016\/j.intimp.2022.109325_b0890","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.cyto.2014.12.007","article-title":"Diallyl disulfide inhibits TNF\u03b1 induced CCL2 release through MAPK\/ERK and NF-Kappa-B signaling","volume":"75","author":"Bauer","year":"2015","journal-title":"Cytokine"},{"issue":"12","key":"10.1016\/j.intimp.2022.109325_b0895","doi-asserted-by":"crossref","first-page":"5919","DOI":"10.21873\/anticanres.15411","article-title":"Effect of Diallyl Trisulfide on TNF-\u03b1-induced CCL2\/MCP-1 Release in Genetically Different Triple-negative Breast Cancer Cells","volume":"41","author":"Kanga","year":"2021","journal-title":"Anticancer Res."},{"issue":"1","key":"10.1016\/j.intimp.2022.109325_b0900","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.medj.2020.11.005","article-title":"The Potential for Repurposing Anti-TNF as a Therapy for the Treatment of COVID-19","volume":"1","author":"Robinson","year":"2020","journal-title":"Med"},{"issue":"1","key":"10.1016\/j.intimp.2022.109325_b0905","doi-asserted-by":"crossref","first-page":"159","DOI":"10.4161\/cc.11.1.18559","article-title":"Bindarit: an anti-inflammatory small molecule that modulates the NFkB pathway","volume":"11","author":"Mora","year":"2012","journal-title":"Cell Cycle"},{"issue":"3","key":"10.1016\/j.intimp.2022.109325_b0910","first-page":"119","article-title":"Impact of the anti-inflammatory agent bindarit on the chemokinome: selective inhibition of the monocyte chemotactic proteins","volume":"19","author":"Mirolo","year":"2008","journal-title":"Eur. Cytokine Netw."},{"issue":"2","key":"10.1016\/j.intimp.2022.109325_b0915","doi-asserted-by":"crossref","first-page":"281","DOI":"10.3233\/JAD-131070","article-title":"Bindarit, inhibitor of CCL2 synthesis, protects neurons against amyloid-\u03b2-induced toxicity","volume":"38","author":"Severini","year":"2014","journal-title":"Journal of Alzheimer's Disease"},{"issue":"1","key":"10.1016\/j.intimp.2022.109325_b0920","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1742-2094-9-171","article-title":"The CCL2 synthesis inhibitor bindarit targets cells of the neurovascular unit, and suppresses experimental autoimmune encephalomyelitis","volume":"9","author":"Ge","year":"2012","journal-title":"Journal of neuroinflammation"},{"issue":"9","key":"10.1016\/j.intimp.2022.109325_b0925","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1038\/s41423-020-0500-1","article-title":"Inhibition of CCL2 by bindarit alleviates diabetes-associated periodontitis by suppressing inflammatory monocyte infiltration and altering macrophage properties","volume":"18","author":"Shen","year":"2021","journal-title":"Cell. Mol. Immunol."},{"issue":"4","key":"10.1016\/j.intimp.2022.109325_b0930","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1159\/000330685","article-title":"Antiproteinuric effect of chemokine CC motif ligand 2 inhibition in subjects with acute proliferative lupus nephritis","volume":"34","author":"Ble","year":"2011","journal-title":"Am. J. Nephrol."},{"issue":"9","key":"10.1016\/j.intimp.2022.109325_b0935","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1038\/nbt0996-1112","article-title":"Mirror-image RNA that binds D-adenosine","volume":"14","author":"Klussmann","year":"1996","journal-title":"Nat. Biotechnol."},{"issue":"1","key":"10.1016\/j.intimp.2022.109325_b0940","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/ncomms7923","article-title":"Crystal structure of a mirror-image L-RNA aptamer (Spiegelmer) in complex with the natural L-protein target CCL2","volume":"6","author":"Oberth\u00fcr","year":"2015","journal-title":"Nat. Commun."},{"issue":"2","key":"10.1016\/j.intimp.2022.109325_b0945","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1093\/ndt\/gfv459","article-title":"CC motif-ligand 2 inhibition with emapticap pegol (NOX-E36) in type 2 diabetic patients with albuminuria","volume":"32","author":"Menne","year":"2017","journal-title":"Nephrol. Dial. Transplant."},{"issue":"8","key":"10.1016\/j.intimp.2022.109325_b0950","doi-asserted-by":"crossref","first-page":"2350","DOI":"10.1681\/ASN.2006121348","article-title":"Spiegelmer inhibition of CCL2\/MCP-1 ameliorates lupus nephritis in MRL-(Fas) lpr mice","volume":"18","author":"Kulkarni","year":"2007","journal-title":"J. Am. Soc. Nephrol."},{"issue":"10","key":"10.1016\/j.intimp.2022.109325_b0955","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1158\/1535-7163.MCT-16-0153","article-title":"A novel small molecule activator of nuclear receptor SHP inhibits HCC cell migration via suppressing Ccl2","volume":"15","author":"Yang","year":"2016","journal-title":"Mol. Cancer Ther."},{"issue":"8","key":"10.1016\/j.intimp.2022.109325_b0960","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.bbadis.2010.10.006","article-title":"Role of nuclear receptor SHP in metabolism and cancer","volume":"1812","author":"Zhang","year":"2011","journal-title":"Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease"},{"key":"10.1016\/j.intimp.2022.109325_b0965","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1146\/annurev-pharmtox-010715-103209","article-title":"Nuclear receptors as therapeutic targets in liver disease: are we there yet?","volume":"56","author":"Rudraiah","year":"2016","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.intimp.2022.109325_b0970","doi-asserted-by":"crossref","DOI":"10.1096\/fasebj.31.1_supplement.328.4","article-title":"A novel hepatocyte SHP\/CCL2 axis controls liver inflammation in NAFL to NASH transition","volume":"31","author":"Magee","year":"2017","journal-title":"FASEB J."},{"key":"10.1016\/j.intimp.2022.109325_b0975","doi-asserted-by":"crossref","unstructured":"Q. Zhao et al., Preclinical antitumor activity of a CC chemokine receptor (CCR) 2\/5 dual antagonist as monotherapy and in combination with immune checkpoint blockade. 2018, AACR.","DOI":"10.1158\/1538-7445.AM2018-3760"},{"issue":"11","key":"10.1016\/j.intimp.2022.109325_b0980","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1021\/acsmedchemlett.1c00373","article-title":"BMS-813160: a potent CCR2 and CCR5 dual antagonist selected as a clinical candidate","volume":"12","author":"Cherney","year":"2021","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.intimp.2022.109325_b0985","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ijid.2020.10.101","article-title":"CCR5 inhibition in critical COVID-19 patients decreases inflammatory cytokines, increases CD8 T-cells, and decreases SARS-CoV2 RNA in plasma by day 14","volume":"103","author":"Patterson","year":"2021","journal-title":"Int. J. Infect. Dis."},{"issue":"5","key":"10.1016\/j.intimp.2022.109325_b0990","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1007\/s00125-009-1309-8","article-title":"Inhibition of the chemokine (C\u2013C motif) ligand 2\/chemokine (C\u2013C motif) receptor 2 pathway attenuates hyperglycaemia and inflammation in a mouse model of hepatic steatosis and lipoatrophy","volume":"52","author":"Yang","year":"2009","journal-title":"Diabetologia"},{"issue":"7","key":"10.1016\/j.intimp.2022.109325_b0995","doi-asserted-by":"crossref","first-page":"e3319","DOI":"10.1002\/dmrr.3319","article-title":"Diabetes is a risk factor for the progression and prognosis of COVID-19","volume":"36","author":"Guo","year":"2020","journal-title":"Diabetes\/metabolism Res. Rev."},{"issue":"6","key":"10.1016\/j.intimp.2022.109325_b1000","doi-asserted-by":"crossref","DOI":"10.1016\/j.cmet.2020.04.021","article-title":"Association of blood glucose control and outcomes in patients with COVID-19 and pre-existing type 2 diabetes","volume":"31","author":"Zhu","year":"2020","journal-title":"Cell Metab."},{"issue":"10","key":"10.1016\/j.intimp.2022.109325_b1005","doi-asserted-by":"crossref","first-page":"e13038","DOI":"10.15252\/emmm.202013038","article-title":"Monocytopenia, monocyte morphological anomalies and hyperinflammation characterise severe COVID-19 in type 2 diabetes","volume":"12","author":"Alzaid","year":"2020","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.intimp.2022.109325_b1010","unstructured":"C. Fong, Covid-19: Predicting inhibition of SARS-CoV-2 in Caco-2 cells: viral cellular entry. 2020, Eigenenergy, Adelaide, Australia."},{"issue":"9","key":"10.1016\/j.intimp.2022.109325_b1015","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S2213-8587(15)00261-2","article-title":"The effect of CCR2 inhibitor CCX140-B on residual albuminuria in patients with type 2 diabetes and nephropathy: a randomised trial","volume":"3","author":"de Zeeuw","year":"2015","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"24","key":"10.1016\/j.intimp.2022.109325_b1020","doi-asserted-by":"crossref","first-page":"39230","DOI":"10.18632\/oncotarget.16837","article-title":"Targeting CCR2 with its antagonist suppresses viability, motility and invasion by downregulating MMP-9 expression in non-small cell lung cancer cells","volume":"8","author":"An","year":"2017","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.intimp.2022.109325_b1025","first-page":"1","article-title":"Endogenous CCL2 neutralization restricts HIV-1 replication in primary human macrophages by inhibiting viral DNA accumulation","volume":"12","author":"Sabbatucci","year":"2015","journal-title":"Retrovirology"},{"issue":"4","key":"10.1016\/j.intimp.2022.109325_b1030","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1080\/13550280600873819","article-title":"Anti-CCL2 treatment inhibits Theiler's murine encephalomyelitis virus-induced demyelinating disease","volume":"12","author":"Karpus","year":"2006","journal-title":"J. Neurovirol."},{"issue":"4","key":"10.1016\/j.intimp.2022.109325_b1035","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.4049\/jimmunol.180.4.2562","article-title":"CCR2+ monocyte-derived dendritic cells and exudate macrophages produce influenza-induced pulmonary immune pathology and mortality","volume":"180","author":"Lin","year":"2008","journal-title":"J. Immunol."},{"issue":"18","key":"10.1016\/j.intimp.2022.109325_b1040","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1056\/NEJMoa2002032","article-title":"Clinical characteristics of coronavirus disease 2019 in China","volume":"382","author":"Guan","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.intimp.2022.109325_b1045","doi-asserted-by":"crossref","first-page":"e1008570","DOI":"10.1371\/journal.ppat.1008570","article-title":"Biological sex impacts COVID-19 outcomes","volume":"16","author":"Klein","year":"2020","journal-title":"PLoS Pathog."},{"issue":"10250","key":"10.1016\/j.intimp.2022.109325_b1050","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0140-6736(20)31561-0","article-title":"Sex and gender: modifiers of health, disease, and medicine","volume":"396","author":"Mauvais-Jarvis","year":"2020","journal-title":"The Lancet"},{"issue":"18","key":"10.1016\/j.intimp.2022.109325_b1055","first-page":"1775","article-title":"Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy","volume":"323","author":"Onder","year":"2020","journal-title":"JAMA"},{"issue":"10","key":"10.1016\/j.intimp.2022.109325_b1060","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.3201\/eid2610.201315","article-title":"COVID-19 national emergency response center, epidemiology and case management team. Contact tracing during coronavirus disease outbreak, South Korea 2020","volume":"26","author":"Park","year":"2020","journal-title":"Emerg. Infect. Dis."},{"issue":"20","key":"10.1016\/j.intimp.2022.109325_b1065","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1001\/jama.2020.6775","article-title":"Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area","volume":"323","author":"Richardson","year":"2020","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.intimp.2022.109325_b1070","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.chest.2021.02.024","article-title":"Progesterone in addition to standard of care vs standard of care alone in the treatment of men hospitalized with moderate to severe COVID-19: a randomized, controlled pilot trial","volume":"160","author":"Ghandehari","year":"2021","journal-title":"Chest"},{"issue":"6","key":"10.1016\/j.intimp.2022.109325_b1075","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1096\/fj.201500116","article-title":"ECL1i, d (LGTFLKC), a novel, small peptide that specifically inhibits CCL2-dependent migration","volume":"30","author":"Auvynet","year":"2016","journal-title":"FASEB J."},{"issue":"6","key":"10.1016\/j.intimp.2022.109325_b1080","doi-asserted-by":"crossref","first-page":"e1010547","DOI":"10.1371\/journal.ppat.1010547","article-title":"Rationale of using the dual chemokine receptor CCR2\/CCR5 inhibitor cenicriviroc for the treatment of COVID-19","volume":"18","author":"Files","year":"2022","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.intimp.2022.109325_b1085","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/497123","article-title":"Evaluation of the effects of some Brazilian medicinal plants on the production of TNF-\u03b1 and CCL2 by THP-1 cells","volume":"2015","author":"Gusman","year":"2015","journal-title":"Evidence-Based Complementary Alternative Med."},{"issue":"2","key":"10.1016\/j.intimp.2022.109325_b1090","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1159\/000494184","article-title":"Shufeng Jiedu capsules alleviate lipopolysaccharide-induced acute lung inflammatory injury via activation of GPR18 by verbenalin","volume":"50","author":"Yuan","year":"2018","journal-title":"Cell. Physiol. Biochem."},{"key":"10.1016\/j.intimp.2022.109325_b1095","doi-asserted-by":"crossref","DOI":"10.1016\/j.jff.2020.104243","article-title":"Systematic analyses on the potential immune and anti-inflammatory mechanisms of Shufeng Jiedu Capsule against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)-caused pneumonia","volume":"75","author":"Tao","year":"2020","journal-title":"J. Funct. Foods"},{"issue":"5","key":"10.1016\/j.intimp.2022.109325_b1100","first-page":"253","article-title":"Complementary and alternative medicine is expected to make greater contribution in controlling the prevalence of influenza","volume":"7","author":"Tao","year":"2013","journal-title":"Biosci. Trends"},{"key":"10.1016\/j.intimp.2022.109325_b1105","doi-asserted-by":"crossref","unstructured":"Y. Liu et al. Study on mechanism of Shufeng Jiedu granules in treating novel coronavirus pneumonia based on network pharmacology, in AIP Conference Proceedings. 2020. AIP Publishing LLC.","DOI":"10.1063\/5.0020374"},{"issue":"8","key":"10.1016\/j.intimp.2022.109325_b1110","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1093\/carcin\/bgm123","article-title":"Curcumin, demethoxycurcumin, bisdemethoxycurcumin, tetrahydrocurcumin and turmerones differentially regulate anti-inflammatory and anti-proliferative responses through a ROS-independent mechanism","volume":"28","author":"Sandur","year":"2007","journal-title":"Carcinogenesis"},{"issue":"01","key":"10.1016\/j.intimp.2022.109325_b1115","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1055\/s-2006-960004","article-title":"Pharmacology of Curcuma longa","volume":"57","author":"Ammon","year":"1991","journal-title":"Planta Med."},{"issue":"1","key":"10.1016\/j.intimp.2022.109325_b1120","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1006\/phrs.1998.0404","article-title":"Curcumin inhibition of inflammatory cytokine production by human peripheral blood monocytes and alveolar macrophages","volume":"39","author":"Abe","year":"1999","journal-title":"Pharmacol. Res."},{"issue":"13","key":"10.1016\/j.intimp.2022.109325_b1125","doi-asserted-by":"crossref","first-page":"9526","DOI":"10.1016\/S0021-9258(18)98383-3","article-title":"Tumor necrosis factor-alpha induces expression of monocyte chemoattractant JE via fos and jun genes in clonal osteoblastic MC3T3-E1 cells","volume":"268","author":"Hanazawa","year":"1993","journal-title":"J. Biol. Chem."},{"issue":"4","key":"10.1016\/j.intimp.2022.109325_b1130","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/j.bcp.2007.08.016","article-title":"Curcumin as \u201cCurecumin\u201d: from kitchen to clinic","volume":"75","author":"Goel","year":"2008","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.intimp.2022.109325_b1135","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/978-0-387-46401-5_4","article-title":"Modulation of transcription factors by curcumin","author":"Shishodia","year":"2007","journal-title":"The molecular targets and therapeutic uses of curcumin in health and disease"},{"issue":"6","key":"10.1016\/j.intimp.2022.109325_b1140","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1007\/s10571-012-9816-4","article-title":"Curcumin inhibits LPS-induced CCL2 expression via JNK pathway in C6 rat astrocytoma cells","volume":"32","author":"Zhang","year":"2012","journal-title":"Cell. Mol. Neurobiol."},{"issue":"5","key":"10.1016\/j.intimp.2022.109325_b1145","doi-asserted-by":"crossref","first-page":"e62482","DOI":"10.1371\/journal.pone.0062482","article-title":"Inhibition of enveloped viruses infectivity by curcumin","volume":"8","author":"Chen","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.intimp.2022.109325_b1150","doi-asserted-by":"crossref","unstructured":"R.Y. Utomo, M. Ikawati, E. Meiyanto, Revealing the potency of citrus and galangal constituents to halt SARS-CoV-2 infection. 2020.","DOI":"10.20944\/preprints202003.0214.v1"},{"issue":"11","key":"10.1016\/j.intimp.2022.109325_b1155","doi-asserted-by":"crossref","first-page":"2911","DOI":"10.1002\/ptr.6738","article-title":"Potential effects of curcumin in the treatment of COVID-19 infection","volume":"34","author":"Zahedipour","year":"2020","journal-title":"Phytother. Res."},{"issue":"2","key":"10.1016\/j.intimp.2022.109325_b1160","article-title":"Curcumin, an inhibitor of PAK1, potential treatment for COVID-19","volume":"3","author":"Nemati","year":"2020","journal-title":"J. Infectiol. Epidemiol."},{"issue":"3","key":"10.1016\/j.intimp.2022.109325_b1165","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1517\/13543770902755129","article-title":"Recent developments in CCR2 antagonists","volume":"19","author":"Xia","year":"2009","journal-title":"Expert Opin. Ther. Pat."},{"issue":"3","key":"10.1016\/j.intimp.2022.109325_b1170","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.4049\/jimmunol.1400551","article-title":"CXCL17 is a major chemotactic factor for lung macrophages","volume":"193","author":"Burkhardt","year":"2014","journal-title":"J. Immunol."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576922008098?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576922008098?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T17:50:07Z","timestamp":1761587407000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576922008098"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":234,"alternative-id":["S1567576922008098"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2022.109325","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Role of CCL2\/CCR2 axis in the pathogenesis of COVID-19 and possible Treatments: All options on the Table","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2022.109325","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"109325"}}